Drug Development in China - CHI, Cambridge Healthtech Institute

Drug Development in China - CHI, Cambridge Healthtech Institute: "

Overview

Zili Li, M.D., Ph.D., Director, Clinical Research Operations, Asia-Pacific, Merck Whaijen Soo, M.D., Ph.D., Senior Vice President, Medical Research, Biogen Idec Edmund Tsuei, Ph.D., Regional Head, Pharma Development Operations, Asia-Pacific-Africa, Roche Products Pty Limited Steve Q. Yang, Ph.D., Head of Research, Asia, Pfizer Global Research & Development Hua Zheng, M.D., Ph.D., Director, Global Regulatory Affairs, Tibotec, Inc. (J&J) Guoxin Zhu, Ph.D., CSO / Head of China Chemistry, Discovery Chemistry Research & Technology, Eli Lilly Asia, Inc.

• Building Critical Strategic Partnerships to Accelerate Drug R&D • Conducting Translational Medicine, Biomarker Validation and Preclinical Safety Studies • Protecting IP & Understanding Barriers and Trends • Understanding the Regulatory Landscape of China • Creating Win-Win Partnerships with Academic Centers • Practical Considerations for Managing Clinical Operations Complimentary Download A Collection of Interviews by Thomson CenterWatch Courtesy of: CenterWatch, a division of Thomson Healthcare Read about business activities by emerging companies involved in global clinical trials. Download now

FEATURING PERSPECTIVES, STRATEGIES, & CASE STUDIES FROM:

•	Balu Balasubramanian, Ph.D., Director, Discovery Chemistry, Bristol-Myers Squibb Co.	•	Eric Meyers, Vice President, Global Initiatives, Cambridge Healthtech Associates
•	Andrew Branca, SVP, Strategic Research, Cambridge Healthtech Associates	•	Lorenz Ng, M.D., CEO, Global Ng Associates, and former Vice President, Research & Alliances, Asia Pacific, Eli Lilly & Co.
•	Michael Chen, President, TCM Group, former Associate Director, Biostatistics and Data Management, Wyeth	•	Helen Niu, M.D., Ph.D., Director, Global Development Operations, Asia & Latin America, Amgen, Inc.
•	Samantha Du, Ph.D., Managing Director, Hutchison MediPharma Ltd.	•	Suresh Poosala DVM, Ph.D., Chief of Comparative Medicine and Animal Program Director, NIH
•	Mark Engel, Chairman, Excel PharmaStudies	•	Chris Song, Manager, Pharmaceutical Segment, Applied Biosystems, former Special Project Manager, AstraZeneca R&D, China
•	Rajiv Gulati, Director, China-India Strategy, Corporate Strategic Planning, Eli Lilly & Co.	•	Whaijen Soo, M.D., Ph.D., Senior Vice President, Medical Research, Biogen Idec
•	Ming Guo, Vice President, Pharmaceutical Science and Manufacturing, Ascenta Therapeutics, Inc.	•	Edmund Tsuei, Ph.D., Regional Head, Pharma Development Operations, Asia-Pacific-Africa, Roche Products Pty Limited
•	Matthew Levy, Director, Protein & Small Molecule Division, Applied Biosystems - China	•	Steve Q. Yang, Ph.D., Head of Research, Asia, Pfizer Global Research & Development
•	Zili Li, M.D., Ph.D., Director, Clinical Research Operations, Asia-Pacific, Merck	•	Hua Zheng, M.D., Ph.D., DABT., RAC, Director, Global Regulatory Affairs, Tibotec, Inc. (J&J)
•	Michael N. Liebman, Ph.D., Executive Director, Windber Research Institute	•	Guoxin Zhu, Ph.D., CSO / Head of China Chemistry, Discovery Chemistry Research & Technology, Eli Lilly Asia, Inc.
•	Mao Mao, M.D., Ph.D., Associate Director/China Project Liaison, Oncology Clinical Research, Merck

"